DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
An independent review board has found Global Blood Therapeutics’ sickle cell disease treatment voxelotor safe, and recommended that its Phase 3 clinical trial continue.
The hallmark of sickle cell disease is damage to a red blood cell protein called hemoglobin that carries oxygen to organs and tissue. The damage causes the cells to become shaped like sickles rather than having a normal disc shape. The sickling interferes with hemoglobin’s ability to deliver oxygen to tissue.
Global Blood designed voxelotor to increase sickle-shaped hemoglobin’s ability to carry oxygen. The primary objective of the 24-week, Phase 3 HOPE trial (NCT03036813) is to see whether voxelotor does increase sickled hemoglobin’s ability to transport oxygen. Patients have been divided into two groups. One is receiving 900 mg of the therapy, and the other 1,500 mg.
education & researchGenetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell...Discovery and validation of genetic vari...
Community CenterPossible Cure for Sickle Cell Found in ParisHematologists, sickle cell patients, and...
education & researchA randomized controlled pilot study feasibility of a tablet-based guided audio-visual relaxation intervention for re...AIM: To test feasibility of a guided aud...
videos & visualsHydroxyurea and Sickle Cell Disease: A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=AyMP3P9E...
news & eventsPhase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
news & eventsLa Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
news & eventsSpectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study FindsThe blood-separation device Spectra Opti...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.